DIVINCELL is a BioPharmaceutical NanoMedicine company pioneering a novel drug delivery technology for the treatment of cancer and genetic diseases. DIVINCELL is specialized in the preclinical and pharmaceutical development of therapeutics using a patented peptide-based delivery platform. DIVINCELL offers innovative solutions to tackle nucleic acid/protein/peptide-based drug cellular uptake limitations, based on 20 years of research in the field of transfection. DIVINCELL is developing and plans to commercialize its innovative drug delivery platform through strategic relationships with established laboratories and pharmaceutical companies. The therapeutics developed by DIVINCELL have been validated using cancer and other therapeutic models (hemophilia, metabolic disorders) and provided an efficient alternative to existing drug delivery methods for a wide range of diseases. This breakthrough technology will have therapeutic potential enabling optimization of treatment accuracy and increasing patient safety.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 442, Rue Georges Besse, Nîmes,occitanie 30900,france
- Industry
- Nanotechnology Research
- NAICS
-
Research and Development in Nanotechnology
- Website
- http://www
- HQ
- Nîmes, Occitanie
Divincell Questions
Divincell's website is http://www
Divincell's LinkedIn profile is https://fr.linkedin.com/company/divincell
Divincell has
5 employees.
View email and phone details for 5
employees at Divincell.
Divincell's industry is
Nanotechnology Research
Divincell's top competitors are
Aanastra Inc,
Vect-Horus,
Acobiom,
Pratico Lab,
Terratis,
Neovacs,
Silence Therapeutics Plc,
Biolum,
Verve Therapeutics,
Christianacare Gene Editing Institute.
Divincell's categories are Nanotechnology Research
Divincell's founding year is 2018
